MTOR and melanoma: By contrast, even though mutations in the catalytic subunit of PI3K, or AKT1, AKT2, and AKT3, are rare in melanoma, immunopositivity of AKT3 is common in melanoma, and could activate PI3K–AKT–mTOR in PTEN wild type tumors.